Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Other 1

Conditions

Obesity 9Endometrial Neoplasms 4Prostatic Neoplasms 2Overweight 2Endometrial Hyperplasia 2Diabetes Mellitus 2Breast Neoplasms 2Weight Loss 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycystic Ovary Syndrome 1Opioid-Related Disorders 1Metabolic Syndrome 1Lymphoma, Follicular 1Insulin Resistance 1Inflammation 1Hyperplasia 1Dyslipidemias 1Colorectal Neoplasms 1

Interventions

Fulvestrant 125Trastuzumab 114Paclitaxel 113Letrozole 108pembrolizumab 79pertuzumab 75palbociclib 75Capecitabine 72Anastrozole 72Cyclophosphamide 70Carboplatin 67abemaciclib 64exemestane 63Tamoxifen 63ribociclib 60trastuzumab deruxtecan 57Surveys and Questionnaires 51Specimen Handling 50Radiotherapy 49Docetaxel 49Magnetic Resonance Spectroscopy 48Blood Specimen Collection 40olaparib 39Standard of Care 36Biopsy 33sacituzumab govitecan 31130-nm albumin-bound paclitaxel 31Doxorubicin 30Exercise 29eribulin 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Breast Neoplasms × Tirzepatide × 1 year × Clear all
NCT07257484 2026-03-13

Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors

Weill Medical College of Cornell University

Phase 4 Not yet recruiting
30 enrolled
BreastOther

Breast Neoplasms, Obesity

NCT06517212 2026-02-12

TRIM-EBC

Baylor Research Institute

Phase 2 Recruiting
48 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡